# Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)

> **NCT04352608** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sinovac Research and Development Co., Ltd.** · enrollment: 744 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
- **BIOLOGICAL:** Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
- **BIOLOGICAL:** Two doses of placebo at the emergency vaccination schedule
- **BIOLOGICAL:** Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
- **BIOLOGICAL:** Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
- **BIOLOGICAL:** Two doses of placebo at the routine vaccination schedule
- **BIOLOGICAL:** Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
- **BIOLOGICAL:** Three doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
- **BIOLOGICAL:** Three doses of placebo at the emergency vaccination schedule
- **BIOLOGICAL:** Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
- **BIOLOGICAL:** Three doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
- **BIOLOGICAL:** Three doses of placebo at the routine vaccination schedule

## Key facts

- **NCT ID:** NCT04352608
- **Lead sponsor:** Sinovac Research and Development Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-16
- **Primary completion:** 2020-07-10
- **Final completion:** 2021-07-24
- **Target enrollment:** 744 (ACTUAL)
- **Last updated:** 2022-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04352608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04352608, "Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04352608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*